Using intervention mapping to facilitate and sustain return-to work after breast cancer: protocol for the FASTRACS multicentre randomized controlled trial
Background Women with breast cancer face many barriers to return to work (RTW) after their cancer. The main objective of the FASTRACS-RCT is to evaluate the impact of the FASTRACS (Facilitate and Sustain Return to Work after Breast Cancer) intervention on the sustainable RTW of breast cancer patient...
Saved in:
| Published in: | BMC cancer Vol. 24; no. 1; pp. 1107 - 12 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
London
BioMed Central
05.09.2024
BioMed Central Ltd Springer Nature B.V BMC |
| Subjects: | |
| ISSN: | 1471-2407, 1471-2407 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Background
Women with breast cancer face many barriers to return to work (RTW) after their cancer. The main objective of the FASTRACS-RCT is to evaluate the impact of the FASTRACS (Facilitate and Sustain Return to Work after Breast Cancer) intervention on the sustainable RTW of breast cancer patients, 12 months after the end of active treatment.
Methods
FASTRACS-RCT is a prospective, national, multicentre, randomized, controlled and open-label study. A total of 420 patients with early breast cancer scheduled for surgery and (neo)adjuvant chemotherapy, will be randomly assigned (1:1 ratio) to: (i) the intervention arm comprising four steps over 6 months : Handing over the intervention tools; transitional medical consultation with the general practitioner (GP); pre-RTW visit with the company’s occupational physician (OP); catch-up visit with a hospital-based RTW expert (if sick leave > 10 months) (ii) the control arm to receive usual care. The design of the FASTRACS intervention was informed by intervention mapping for complex interventions in health promotion planning, and involved patients and representatives of relevant stakeholders. Specific tools were developed to bridge the gap between the hospital, the GP, the OP and the workplace: a toolkit for breast cancer patients comprising a theory-based guide; specific checklists for the GP and the OP, respectively; and a theory-based guide for workplace actors (employer, manager, colleagues). The primary endpoint will associate sustainable RTW (full-time or part-time work at 50% or more of working time, for at least 28 consecutive days) and days off work. It will be assessed at 4, 8 and 12 months after the end of active oncological treatment. Secondary endpoints will include quality of life, anxiety, depression, RTW self-efficacy, physical activity, social support, job accommodations, work productivity, job status, and the usefulness and acceptability of the intervention’s tools.
Discussion
FASTRACS-RCT will be supplemented by a realist evaluation approach aimed at understanding the influence of context in activating the intervention’s mechanisms and effects. If the expected impact of the intervention is confirmed, the intervention will be adapted and scaled-up for other cancers and chronic diseases to better integrate healthcare and work disability prevention.
Trial registration
NCT04846972 ; April 15, 2021. |
|---|---|
| AbstractList | Background
Women with breast cancer face many barriers to return to work (RTW) after their cancer. The main objective of the FASTRACS-RCT is to evaluate the impact of the FASTRACS (Facilitate and Sustain Return to Work after Breast Cancer) intervention on the sustainable RTW of breast cancer patients, 12 months after the end of active treatment.
Methods
FASTRACS-RCT is a prospective, national, multicentre, randomized, controlled and open-label study. A total of 420 patients with early breast cancer scheduled for surgery and (neo)adjuvant chemotherapy, will be randomly assigned (1:1 ratio) to: (i) the intervention arm comprising four steps over 6 months : Handing over the intervention tools; transitional medical consultation with the general practitioner (GP); pre-RTW visit with the company’s occupational physician (OP); catch-up visit with a hospital-based RTW expert (if sick leave > 10 months) (ii) the control arm to receive usual care. The design of the FASTRACS intervention was informed by intervention mapping for complex interventions in health promotion planning, and involved patients and representatives of relevant stakeholders. Specific tools were developed to bridge the gap between the hospital, the GP, the OP and the workplace: a toolkit for breast cancer patients comprising a theory-based guide; specific checklists for the GP and the OP, respectively; and a theory-based guide for workplace actors (employer, manager, colleagues). The primary endpoint will associate sustainable RTW (full-time or part-time work at 50% or more of working time, for at least 28 consecutive days) and days off work. It will be assessed at 4, 8 and 12 months after the end of active oncological treatment. Secondary endpoints will include quality of life, anxiety, depression, RTW self-efficacy, physical activity, social support, job accommodations, work productivity, job status, and the usefulness and acceptability of the intervention’s tools.
Discussion
FASTRACS-RCT will be supplemented by a realist evaluation approach aimed at understanding the influence of context in activating the intervention’s mechanisms and effects. If the expected impact of the intervention is confirmed, the intervention will be adapted and scaled-up for other cancers and chronic diseases to better integrate healthcare and work disability prevention.
Trial registration
NCT04846972 ; April 15, 2021. Abstract Background Women with breast cancer face many barriers to return to work (RTW) after their cancer. The main objective of the FASTRACS-RCT is to evaluate the impact of the FASTRACS (Facilitate and Sustain Return to Work after Breast Cancer) intervention on the sustainable RTW of breast cancer patients, 12 months after the end of active treatment. Methods FASTRACS-RCT is a prospective, national, multicentre, randomized, controlled and open-label study. A total of 420 patients with early breast cancer scheduled for surgery and (neo)adjuvant chemotherapy, will be randomly assigned (1:1 ratio) to: (i) the intervention arm comprising four steps over 6 months : Handing over the intervention tools; transitional medical consultation with the general practitioner (GP); pre-RTW visit with the company’s occupational physician (OP); catch-up visit with a hospital-based RTW expert (if sick leave > 10 months) (ii) the control arm to receive usual care. The design of the FASTRACS intervention was informed by intervention mapping for complex interventions in health promotion planning, and involved patients and representatives of relevant stakeholders. Specific tools were developed to bridge the gap between the hospital, the GP, the OP and the workplace: a toolkit for breast cancer patients comprising a theory-based guide; specific checklists for the GP and the OP, respectively; and a theory-based guide for workplace actors (employer, manager, colleagues). The primary endpoint will associate sustainable RTW (full-time or part-time work at 50% or more of working time, for at least 28 consecutive days) and days off work. It will be assessed at 4, 8 and 12 months after the end of active oncological treatment. Secondary endpoints will include quality of life, anxiety, depression, RTW self-efficacy, physical activity, social support, job accommodations, work productivity, job status, and the usefulness and acceptability of the intervention’s tools. Discussion FASTRACS-RCT will be supplemented by a realist evaluation approach aimed at understanding the influence of context in activating the intervention’s mechanisms and effects. If the expected impact of the intervention is confirmed, the intervention will be adapted and scaled-up for other cancers and chronic diseases to better integrate healthcare and work disability prevention. Trial registration NCT04846972 ; April 15, 2021. Women with breast cancer face many barriers to return to work (RTW) after their cancer. The main objective of the FASTRACS-RCT is to evaluate the impact of the FASTRACS (Facilitate and Sustain Return to Work after Breast Cancer) intervention on the sustainable RTW of breast cancer patients, 12 months after the end of active treatment.BACKGROUNDWomen with breast cancer face many barriers to return to work (RTW) after their cancer. The main objective of the FASTRACS-RCT is to evaluate the impact of the FASTRACS (Facilitate and Sustain Return to Work after Breast Cancer) intervention on the sustainable RTW of breast cancer patients, 12 months after the end of active treatment.FASTRACS-RCT is a prospective, national, multicentre, randomized, controlled and open-label study. A total of 420 patients with early breast cancer scheduled for surgery and (neo)adjuvant chemotherapy, will be randomly assigned (1:1 ratio) to: (i) the intervention arm comprising four steps over 6 months : Handing over the intervention tools; transitional medical consultation with the general practitioner (GP); pre-RTW visit with the company's occupational physician (OP); catch-up visit with a hospital-based RTW expert (if sick leave > 10 months) (ii) the control arm to receive usual care. The design of the FASTRACS intervention was informed by intervention mapping for complex interventions in health promotion planning, and involved patients and representatives of relevant stakeholders. Specific tools were developed to bridge the gap between the hospital, the GP, the OP and the workplace: a toolkit for breast cancer patients comprising a theory-based guide; specific checklists for the GP and the OP, respectively; and a theory-based guide for workplace actors (employer, manager, colleagues). The primary endpoint will associate sustainable RTW (full-time or part-time work at 50% or more of working time, for at least 28 consecutive days) and days off work. It will be assessed at 4, 8 and 12 months after the end of active oncological treatment. Secondary endpoints will include quality of life, anxiety, depression, RTW self-efficacy, physical activity, social support, job accommodations, work productivity, job status, and the usefulness and acceptability of the intervention's tools.METHODSFASTRACS-RCT is a prospective, national, multicentre, randomized, controlled and open-label study. A total of 420 patients with early breast cancer scheduled for surgery and (neo)adjuvant chemotherapy, will be randomly assigned (1:1 ratio) to: (i) the intervention arm comprising four steps over 6 months : Handing over the intervention tools; transitional medical consultation with the general practitioner (GP); pre-RTW visit with the company's occupational physician (OP); catch-up visit with a hospital-based RTW expert (if sick leave > 10 months) (ii) the control arm to receive usual care. The design of the FASTRACS intervention was informed by intervention mapping for complex interventions in health promotion planning, and involved patients and representatives of relevant stakeholders. Specific tools were developed to bridge the gap between the hospital, the GP, the OP and the workplace: a toolkit for breast cancer patients comprising a theory-based guide; specific checklists for the GP and the OP, respectively; and a theory-based guide for workplace actors (employer, manager, colleagues). The primary endpoint will associate sustainable RTW (full-time or part-time work at 50% or more of working time, for at least 28 consecutive days) and days off work. It will be assessed at 4, 8 and 12 months after the end of active oncological treatment. Secondary endpoints will include quality of life, anxiety, depression, RTW self-efficacy, physical activity, social support, job accommodations, work productivity, job status, and the usefulness and acceptability of the intervention's tools.FASTRACS-RCT will be supplemented by a realist evaluation approach aimed at understanding the influence of context in activating the intervention's mechanisms and effects. If the expected impact of the intervention is confirmed, the intervention will be adapted and scaled-up for other cancers and chronic diseases to better integrate healthcare and work disability prevention.DISCUSSIONFASTRACS-RCT will be supplemented by a realist evaluation approach aimed at understanding the influence of context in activating the intervention's mechanisms and effects. If the expected impact of the intervention is confirmed, the intervention will be adapted and scaled-up for other cancers and chronic diseases to better integrate healthcare and work disability prevention.NCT04846972 ; April 15, 2021.TRIAL REGISTRATIONNCT04846972 ; April 15, 2021. Women with breast cancer face many barriers to return to work (RTW) after their cancer. The main objective of the FASTRACS-RCT is to evaluate the impact of the FASTRACS (Facilitate and Sustain Return to Work after Breast Cancer) intervention on the sustainable RTW of breast cancer patients, 12 months after the end of active treatment. FASTRACS-RCT is a prospective, national, multicentre, randomized, controlled and open-label study. A total of 420 patients with early breast cancer scheduled for surgery and (neo)adjuvant chemotherapy, will be randomly assigned (1:1 ratio) to: (i) the intervention arm comprising four steps over 6 months : Handing over the intervention tools; transitional medical consultation with the general practitioner (GP); pre-RTW visit with the company's occupational physician (OP); catch-up visit with a hospital-based RTW expert (if sick leave > 10 months) (ii) the control arm to receive usual care. The design of the FASTRACS intervention was informed by intervention mapping for complex interventions in health promotion planning, and involved patients and representatives of relevant stakeholders. Specific tools were developed to bridge the gap between the hospital, the GP, the OP and the workplace: a toolkit for breast cancer patients comprising a theory-based guide; specific checklists for the GP and the OP, respectively; and a theory-based guide for workplace actors (employer, manager, colleagues). The primary endpoint will associate sustainable RTW (full-time or part-time work at 50% or more of working time, for at least 28 consecutive days) and days off work. It will be assessed at 4, 8 and 12 months after the end of active oncological treatment. Secondary endpoints will include quality of life, anxiety, depression, RTW self-efficacy, physical activity, social support, job accommodations, work productivity, job status, and the usefulness and acceptability of the intervention's tools. FASTRACS-RCT will be supplemented by a realist evaluation approach aimed at understanding the influence of context in activating the intervention's mechanisms and effects. If the expected impact of the intervention is confirmed, the intervention will be adapted and scaled-up for other cancers and chronic diseases to better integrate healthcare and work disability prevention. BackgroundWomen with breast cancer face many barriers to return to work (RTW) after their cancer. The main objective of the FASTRACS-RCT is to evaluate the impact of the FASTRACS (Facilitate and Sustain Return to Work after Breast Cancer) intervention on the sustainable RTW of breast cancer patients, 12 months after the end of active treatment.MethodsFASTRACS-RCT is a prospective, national, multicentre, randomized, controlled and open-label study. A total of 420 patients with early breast cancer scheduled for surgery and (neo)adjuvant chemotherapy, will be randomly assigned (1:1 ratio) to: (i) the intervention arm comprising four steps over 6 months : Handing over the intervention tools; transitional medical consultation with the general practitioner (GP); pre-RTW visit with the company’s occupational physician (OP); catch-up visit with a hospital-based RTW expert (if sick leave > 10 months) (ii) the control arm to receive usual care. The design of the FASTRACS intervention was informed by intervention mapping for complex interventions in health promotion planning, and involved patients and representatives of relevant stakeholders. Specific tools were developed to bridge the gap between the hospital, the GP, the OP and the workplace: a toolkit for breast cancer patients comprising a theory-based guide; specific checklists for the GP and the OP, respectively; and a theory-based guide for workplace actors (employer, manager, colleagues). The primary endpoint will associate sustainable RTW (full-time or part-time work at 50% or more of working time, for at least 28 consecutive days) and days off work. It will be assessed at 4, 8 and 12 months after the end of active oncological treatment. Secondary endpoints will include quality of life, anxiety, depression, RTW self-efficacy, physical activity, social support, job accommodations, work productivity, job status, and the usefulness and acceptability of the intervention’s tools.DiscussionFASTRACS-RCT will be supplemented by a realist evaluation approach aimed at understanding the influence of context in activating the intervention’s mechanisms and effects. If the expected impact of the intervention is confirmed, the intervention will be adapted and scaled-up for other cancers and chronic diseases to better integrate healthcare and work disability prevention.Trial registrationNCT04846972 ; April 15, 2021. Women with breast cancer face many barriers to return to work (RTW) after their cancer. The main objective of the FASTRACS-RCT is to evaluate the impact of the FASTRACS (Facilitate and Sustain Return to Work after Breast Cancer) intervention on the sustainable RTW of breast cancer patients, 12 months after the end of active treatment. FASTRACS-RCT is a prospective, national, multicentre, randomized, controlled and open-label study. A total of 420 patients with early breast cancer scheduled for surgery and (neo)adjuvant chemotherapy, will be randomly assigned (1:1 ratio) to: (i) the intervention arm comprising four steps over 6 months : Handing over the intervention tools; transitional medical consultation with the general practitioner (GP); pre-RTW visit with the company's occupational physician (OP); catch-up visit with a hospital-based RTW expert (if sick leave > 10 months) (ii) the control arm to receive usual care. The design of the FASTRACS intervention was informed by intervention mapping for complex interventions in health promotion planning, and involved patients and representatives of relevant stakeholders. Specific tools were developed to bridge the gap between the hospital, the GP, the OP and the workplace: a toolkit for breast cancer patients comprising a theory-based guide; specific checklists for the GP and the OP, respectively; and a theory-based guide for workplace actors (employer, manager, colleagues). The primary endpoint will associate sustainable RTW (full-time or part-time work at 50% or more of working time, for at least 28 consecutive days) and days off work. It will be assessed at 4, 8 and 12 months after the end of active oncological treatment. Secondary endpoints will include quality of life, anxiety, depression, RTW self-efficacy, physical activity, social support, job accommodations, work productivity, job status, and the usefulness and acceptability of the intervention's tools. FASTRACS-RCT will be supplemented by a realist evaluation approach aimed at understanding the influence of context in activating the intervention's mechanisms and effects. If the expected impact of the intervention is confirmed, the intervention will be adapted and scaled-up for other cancers and chronic diseases to better integrate healthcare and work disability prevention. NCT04846972 ; April 15, 2021. Background Women with breast cancer face many barriers to return to work (RTW) after their cancer. The main objective of the FASTRACS-RCT is to evaluate the impact of the FASTRACS (Facilitate and Sustain Return to Work after Breast Cancer) intervention on the sustainable RTW of breast cancer patients, 12 months after the end of active treatment. Methods FASTRACS-RCT is a prospective, national, multicentre, randomized, controlled and open-label study. A total of 420 patients with early breast cancer scheduled for surgery and (neo)adjuvant chemotherapy, will be randomly assigned (1:1 ratio) to: (i) the intervention arm comprising four steps over 6 months : Handing over the intervention tools; transitional medical consultation with the general practitioner (GP); pre-RTW visit with the company's occupational physician (OP); catch-up visit with a hospital-based RTW expert (if sick leave > 10 months) (ii) the control arm to receive usual care. The design of the FASTRACS intervention was informed by intervention mapping for complex interventions in health promotion planning, and involved patients and representatives of relevant stakeholders. Specific tools were developed to bridge the gap between the hospital, the GP, the OP and the workplace: a toolkit for breast cancer patients comprising a theory-based guide; specific checklists for the GP and the OP, respectively; and a theory-based guide for workplace actors (employer, manager, colleagues). The primary endpoint will associate sustainable RTW (full-time or part-time work at 50% or more of working time, for at least 28 consecutive days) and days off work. It will be assessed at 4, 8 and 12 months after the end of active oncological treatment. Secondary endpoints will include quality of life, anxiety, depression, RTW self-efficacy, physical activity, social support, job accommodations, work productivity, job status, and the usefulness and acceptability of the intervention's tools. Discussion FASTRACS-RCT will be supplemented by a realist evaluation approach aimed at understanding the influence of context in activating the intervention's mechanisms and effects. If the expected impact of the intervention is confirmed, the intervention will be adapted and scaled-up for other cancers and chronic diseases to better integrate healthcare and work disability prevention. Trial registration NCT04846972 ; April 15, 2021. Keywords: Breast neoplasms, Cancer survivors, Intervention studies, Theory-driven evaluation, Work disability prevention, Return to work, Intervention mapping, General practitioner, Occupational health physician, Self-efficacy Background: Women with breast cancer face many barriers to return to work (RTW) after their cancer. The main objective of the FASTRACS-RCT is to evaluate the impact of the FASTRACS (Facilitate and Sustain Return to Work after Breast Cancer) intervention on the sustainable RTW of breast cancer patients, 12 months after the end of active treatment.Methods: FASTRACS-RCT is a prospective, national, multicentre, randomized, controlled and open-label study. A total of 420 patients with early breast cancer scheduled for surgery and (neo)adjuvant chemotherapy, will be randomly assigned (1:1 ratio) to: (i) the intervention arm comprising four steps over 6 months : Handing over the intervention tools; transitional medical consultation with the general practitioner (GP); pre-RTW visit with the company's occupational physician (OP); catch-up visit with a hospital-based RTW expert (if sick leave > 10 months) (ii) the control arm to receive usual care. The design of the FASTRACS intervention was informed by intervention mapping for complex interventions in health promotion planning, and involved patients and representatives of relevant stakeholders. Specific tools were developed to bridge the gap between the hospital, the GP, the OP and the workplace: a toolkit for breast cancer patients comprising a theory-based guide; specific checklists for the GP and the OP, respectively; and a theory-based guide for workplace actors (employer, manager, colleagues). The primary endpoint will associate sustainable RTW (full-time or part-time work at 50% or more of working time, for at least 28 consecutive days) and days off work. It will be assessed at 4, 8 and 12 months after the end of active oncological treatment. Secondary endpoints will include quality of life, anxiety, depression, RTW self-efficacy, physical activity, social support, job accommodations, work productivity, job status, and the usefulness and acceptability of the intervention's tools.Discussion: FASTRACS-RCT will be supplemented by a realist evaluation approach aimed at understanding the influence of context in activating the intervention's mechanisms and effects. If the expected impact of the intervention is confirmed, the intervention will be adapted and scaled-up for other cancers and chronic diseases to better integrate healthcare and work disability prevention.Trial registration: NCT04846972 ; April 15, 2021. |
| ArticleNumber | 1107 |
| Audience | Academic |
| Author | Péron, Julien Guittard, Laure Fassier, Jean-Baptiste Fervers, Béatrice Rouat, Sabrina Carretier, Julien Broc, Guillaume Letrilliart, Laurent Sarnin, Philippe Lamort-Bouché, Marion |
| Author_xml | – sequence: 1 givenname: Jean-Baptiste surname: Fassier fullname: Fassier, Jean-Baptiste email: jean-baptiste.fassier@univ-lyon1.fr organization: Université Claude Bernard Lyon 1, Université Gustave Eiffel, UMRESTTE UMR T9405, Hospices Civils de Lyon, Service de Médecine et Santé au Travail, Pôle de Santé Publique – sequence: 2 givenname: Laure surname: Guittard fullname: Guittard, Laure organization: Hospices Civils de Lyon, Service Recherche et Epidémiologie Cliniques, Pôle de Santé Publique, Research on Healthcare Performance RESHAPE, Université Claude Bernard Lyon 1, INSERM U1290 – sequence: 3 givenname: Béatrice surname: Fervers fullname: Fervers, Béatrice organization: Centre Léon Bérard (CLB), Départment Cancer et Environment, Radiations: Defense, Health & Environment, INSERM U1296 – sequence: 4 givenname: Sabrina surname: Rouat fullname: Rouat, Sabrina organization: Université Lumière Lyon 2, GREPS EA 4163 – sequence: 5 givenname: Philippe surname: Sarnin fullname: Sarnin, Philippe organization: Université Lumière Lyon 2, GREPS EA 4163 – sequence: 6 givenname: Julien surname: Carretier fullname: Carretier, Julien organization: Université Claude Bernard Lyon 1, Centre National des Soins Palliatifs et de La Fin de Vie – sequence: 7 givenname: Guillaume surname: Broc fullname: Broc, Guillaume organization: Université Paul-Valéry Montpellier 3 – sequence: 8 givenname: Laurent surname: Letrilliart fullname: Letrilliart, Laurent organization: Research on Healthcare Performance RESHAPE, Université Claude Bernard Lyon 1, INSERM U1290, Université Claude Bernard Lyon 1, University General Practice Department (CUMG) – sequence: 9 givenname: Julien surname: Péron fullname: Péron, Julien organization: Research on Healthcare Performance RESHAPE, Université Claude Bernard Lyon 1, INSERM U1290, Service D’oncologie médicale, Hospices Civils de Lyon, Institut de Cancérologie – sequence: 10 givenname: Marion surname: Lamort-Bouché fullname: Lamort-Bouché, Marion organization: Research on Healthcare Performance RESHAPE, Université Claude Bernard Lyon 1, INSERM U1290, Université Claude Bernard Lyon 1, University General Practice Department (CUMG) |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39237867$$D View this record in MEDLINE/PubMed https://hal.science/hal-04707791$$DView record in HAL |
| BookMark | eNp9kttq3DAQhk1JaQ7tC_SiCAqluXCqg9eWe7csTRMIFLLJtZiVx7vaytZWktPDo_RpK2fTNBtK0IXE8P2_pJn_MNvrXY9Z9prRE8Zk-SEwLuUkp7zIGa_qMi-eZQesqFjOC1rtPTjvZ4chrClllaTyRbYvai4qWVYH2e_rYPolMX1Ef4N9NK4nHWw2YzE60oI21kSISKBvSBhCBNMTj3HwfZ6A785_JdAmNVl4hBCJhl6j_0g23kWnnSWt8ySukJxO51eX09mcdIONRqfLPBKfbF1nfmFDtEsVZ206Rm_Avsyet2ADvrrbj7Lr009Xs7P84svn89n0ItflhMVci9QFLlteC84EFZMGSsoavRAtsKKhTVtKCUgFCpr2WgshKTDNJ-1iImUjjrLzrW_jYK023nTgfyoHRt0WnF8q8OnBFlWFULFSsCJdVtBJU5fYgsC6rlC3i0Ikr-Ot1wrsjtXZ9EKNNVpUtKpqdsMS-37Lpk59GzBE1Zmg0Vro0Q1BCUYZ5zWVdULfPkLXLg0gdWWkeCF5lX5-Ty0hvdX0rYse9GiqpmnuQrCaF4k6-Q-VVoOdSTPA1qT6juB4RzDOCX_EJQwhqPP55S777gG7QrBxFZwdxlyFXfDN3Y-GRYfNfa_-JjMBfAto70Lw2N4jjKox_mobf5W-r27jr0ZX-Uikx_CaMVlg7NNSsZWGdE-_RP-vxU-o_gDlfBYT |
| CitedBy_id | crossref_primary_10_1155_ecc_5333340 crossref_primary_10_3390_curroncol32050266 |
| Cites_doi | 10.32604/po.2023.044730 10.1002/pon.4514 10.1136/bmj.h1258 10.1016/j.ejca.2021.07.039 10.3322/caac.21708 10.1016/j.cnd.2012.04.002 10.1016/j.admp.2020.01.002 10.1037/0033-295X.84.2.191 10.1037/h0088437 10.1016/S0140-6736(12)61228-8 10.1002/sim.3923 10.1136/oem.2004.013896 10.1200/JCO.1996.14.10.2756 10.1200/JCO.19.01726 10.1007/s40273-019-00876-4 10.1177/0962280216658320 10.4135/9781071909850 10.1016/j.healthpol.2010.06.013 10.1007/s11764-022-01211-1 10.3233/WOR-182810 10.1186/s13058-023-01623-6 10.3390/curroncol28050330 10.1007/s10926-018-9800-z 10.1007/s10926-018-9776-8 10.1186/1479-5868-8-115 10.1002/14651858.CD007569.pub3 10.1016/j.bulcan.2021.06.016 10.1007/s10926-005-8031-2 10.1200/JCO.2017.77.3663 10.1186/1471-2458-14-S3-S8 10.1093/jnci/85.5.365 10.1200/JCO.19.01856 10.1111/j.1600-0447.1983.tb09716.x 10.1007/BF03405503 10.1186/s12885-021-08613-x 10.3389/fpubh.2018.00035 10.5271/sjweh.3847 10.1186/s13045-019-0828-0 10.1007/s10926-017-9697-y 10.1007/s11764-022-01197-w 10.1007/s00520-019-05189-y 10.1080/02678373.2010.532644 10.2165/00019053-200321050-00004 10.1186/s12955-016-0489-4 10.1016/j.jalz.2012.06.008 10.1097/00004356-200412000-00002 10.1007/s10926-009-9172-5 10.1177/1356389016652743 10.1001/jama.2009.187 10.1002/pon.4611 10.1177/1757975921993358 10.1136/bmj.n2061 10.1016/j.socscimed.2012.08.032 10.1007/s00520-016-3526-2 10.3389/fpsyg.2022.910779 10.1186/s12889-022-14271-w 10.1016/S0277-9536(99)00452-9 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2024 2024. The Author(s). COPYRIGHT 2024 BioMed Central Ltd. 2024. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Copyright |
| Copyright_xml | – notice: The Author(s) 2024 – notice: 2024. The Author(s). – notice: COPYRIGHT 2024 BioMed Central Ltd. – notice: 2024. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Copyright |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM ISR 3V. 7TO 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 1XC DOA |
| DOI | 10.1186/s12885-024-12796-4 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Science ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection ProQuest Medical Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic Hyper Article en Ligne (HAL) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2407 |
| EndPage | 12 |
| ExternalDocumentID | oai_doaj_org_article_7ea716314293405d96efa3e997ecfb43 oai:HAL:hal-04707791v1 A808331924 39237867 10_1186_s12885_024_12796_4 |
| Genre | Clinical Trial Protocol Journal Article |
| GeographicLocations | France |
| GeographicLocations_xml | – name: France |
| GrantInformation_xml | – fundername: Institut National Du Cancer grantid: INCa Amorçage, RISP no 2016-003 funderid: http://dx.doi.org/10.13039/501100006364 – fundername: Direction Régionale de l’économie, de l’emploi, du travail, et des solidarités (DREETS) Auvergne Rhône Alpes grantid: 2017–2018 – fundername: Métropole du Grand Lyon grantid: Délibération 2016-1445 projets structurants 2016 2017 – fundername: Financement mixte avec la Caisse de Retraite et de Prévoyance des Clercs et Employés de Notaires – fundername: Cancéropôle Auvergne Rhône Alpes (CLARA) grantid: AAP ONCOSTARTER 2016 – fundername: Institut National du Cancer grantid: INCa, RISP no 2018-025 – fundername: Association nationale de GEstion du Fonds pour l’Insertion Professionnelle des personnes Handicapées (Agefiph) et Direction Régionale des Entreprises, de la Concurrence, de la Consommation, du Travail et de l’Emploi (DIRECCTE, nouvellement DREETS ) grantid: Appel à initiatives 2020 – fundername: Association nationale de GEstion du Fonds pour l'Insertion Professionnelle des personnes Handicapées (Agefiph) et Direction Régionale des Entreprises, de la Concurrence, de la Consommation, du Travail et de l'Emploi (DIRECCTE, nouvellement DREETS ) grantid: Appel à initiatives 2020 – fundername: Institut National Du Cancer grantid: INCa Amorçage, RISP no 2016-003 – fundername: Direction Régionale de l'économie, de l'emploi, du travail, et des solidarités (DREETS) Auvergne Rhône Alpes grantid: 2017-2018 |
| GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACMJI ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR IHW INH INR ISR ITC KQ8 LGEZI LOTEE M1P M48 M~E NADUK NXXTH O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS U2A UKHRP W2D WOQ WOW XSB AAYXX AFFHD CITATION ALIPV CGR CUY CVF ECM EIF NPM 3V. 7TO 7XB 8FK AEUYN AZQEC DWQXO H94 K9. PKEHL PQEST PQUKI PRINS 7X8 1XC |
| ID | FETCH-LOGICAL-c651t-c328828f293213035da601dcb3fa14d0df688ae03e308ae9c3380a1c25fb588d3 |
| IEDL.DBID | RSV |
| ISICitedReferencesCount | 3 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001307893300007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1471-2407 |
| IngestDate | Fri Oct 03 12:43:54 EDT 2025 Tue Oct 14 20:55:24 EDT 2025 Thu Oct 02 05:57:32 EDT 2025 Tue Oct 07 05:47:13 EDT 2025 Sat Nov 29 13:56:29 EST 2025 Sat Nov 29 10:33:37 EST 2025 Wed Nov 26 11:28:40 EST 2025 Thu May 22 21:23:11 EDT 2025 Mon Jul 21 06:06:16 EDT 2025 Tue Nov 18 20:49:34 EST 2025 Sat Nov 29 06:43:04 EST 2025 Sat Sep 06 07:17:30 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Cancer survivors Occupational health physician Work disability prevention General practitioner Self-efficacy Breast neoplasms Intervention mapping Intervention studies Theory-driven evaluation Return to work |
| Language | English |
| License | 2024. The Author(s). Copyright: http://hal.archives-ouvertes.fr/licences/copyright |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c651t-c328828f293213035da601dcb3fa14d0df688ae03e308ae9c3380a1c25fb588d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://link.springer.com/10.1186/s12885-024-12796-4 |
| PMID | 39237867 |
| PQID | 3102482730 |
| PQPubID | 44074 |
| PageCount | 12 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_7ea716314293405d96efa3e997ecfb43 hal_primary_oai_HAL_hal_04707791v1 proquest_miscellaneous_3101229089 proquest_journals_3102482730 gale_infotracmisc_A808331924 gale_infotracacademiconefile_A808331924 gale_incontextgauss_ISR_A808331924 gale_healthsolutions_A808331924 pubmed_primary_39237867 crossref_primary_10_1186_s12885_024_12796_4 crossref_citationtrail_10_1186_s12885_024_12796_4 springer_journals_10_1186_s12885_024_12796_4 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-09-05 |
| PublicationDateYYYYMMDD | 2024-09-05 |
| PublicationDate_xml | – month: 09 year: 2024 text: 2024-09-05 day: 05 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | BMC cancer |
| PublicationTitleAbbrev | BMC Cancer |
| PublicationTitleAlternate | BMC Cancer |
| PublicationYear | 2024 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC |
| References | K Bilodeau (12796_CR17) 2017; 25 A Bandura (12796_CR43) 1977; 84 MA Greidanus (12796_CR56) 2019; 29 A Wimo (12796_CR47) 2013; 9 M Lamort-Bouché (12796_CR16) 2020; 46 A Paraponaris (12796_CR15) 2010; 98 G Broc (12796_CR28) 2023; 17 GF Moore (12796_CR61) 2015; 350 K Skivington (12796_CR21) 2021; 374 SE Lagerveld (12796_CR42) 2010; 24 JB Fassier (12796_CR24) 2019; 29 M Viseux (12796_CR54) 2022; 13 C Alleaume (12796_CR14) 2020; 28 NK Aaronson (12796_CR38) 1993; 85 A Fletcher (12796_CR30) 2016; 22 L Wang (12796_CR8) 2018; 36 12796_CR52 M-J Durand (12796_CR49) 2004; 27 LF Andrade (12796_CR39) 2020; 38 B Porro (12796_CR55) 2022; 22 12796_CR57 JE Ferrie (12796_CR34) 2005; 62 AGEM de Boer (12796_CR6) 2009; 301 M-C Sarfo (12796_CR31) 2023; 17 M Lamort-Bouché (12796_CR23) 2018; 27 N Algeo (12796_CR19) 2021; 21 S Brouwer (12796_CR59) 2009; 19 J-B Fassier (12796_CR27) 2018; 6 12796_CR60 A Vuillemin (12796_CR45) 2012; 47 A-L Rolland (12796_CR7) 2023; 25 12796_CR22 12796_CR4 12796_CR25 12796_CR26 RA Cocchiara (12796_CR10) 2018; 61 E Caumette (12796_CR12) 2022 12796_CR18 P Loisel (12796_CR20) 2005; 15 VS Blinder (12796_CR5) 2020; 38 M Buyse (12796_CR50) 2010; 29 RL Siegel (12796_CR3) 2022; 72 T Islam (12796_CR9) 2014; 14 JM Giesinger (12796_CR36) 2016; 14 N Li (12796_CR1) 2019; 12 AS Zigmond (12796_CR40) 1983; 67 MA Sprangers (12796_CR37) 1996; 14 B Porro (12796_CR41) 2022; 109 T Dyba (12796_CR2) 2021; 157 U Bronfenbrenner (12796_CR58) 2006 12796_CR33 C Bonell (12796_CR29) 2012; 75 A Dumas (12796_CR11) 2020; 38 J Péron (12796_CR51) 2018; 27 PH Lee (12796_CR46) 2011; 8 JL Severens (12796_CR35) 2000; 51 O Black (12796_CR44) 2018; 28 MA Greidanus (12796_CR32) 2018; 27 A Wimo (12796_CR48) 2003; 21 E Caumette (12796_CR13) 2021; 28 M Marmot (12796_CR53) 2012; 380 |
| References_xml | – volume: 17 start-page: 167 year: 2023 ident: 12796_CR28 publication-title: Psycho-Oncologie doi: 10.32604/po.2023.044730 – volume: 27 start-page: 725 year: 2018 ident: 12796_CR32 publication-title: Psychooncology doi: 10.1002/pon.4514 – volume: 350 start-page: h1258 year: 2015 ident: 12796_CR61 publication-title: BMJ doi: 10.1136/bmj.h1258 – ident: 12796_CR4 – volume: 157 start-page: 308 year: 2021 ident: 12796_CR2 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2021.07.039 – volume: 72 start-page: 7 year: 2022 ident: 12796_CR3 publication-title: CA Cancer J Clin doi: 10.3322/caac.21708 – volume: 47 start-page: 234 year: 2012 ident: 12796_CR45 publication-title: Cahiers De Nutr et de Diététique doi: 10.1016/j.cnd.2012.04.002 – ident: 12796_CR26 doi: 10.1016/j.admp.2020.01.002 – volume: 84 start-page: 191 year: 1977 ident: 12796_CR43 publication-title: Psychol Rev doi: 10.1037/0033-295X.84.2.191 – ident: 12796_CR57 doi: 10.1037/h0088437 – volume: 380 start-page: 1011 year: 2012 ident: 12796_CR53 publication-title: Lancet doi: 10.1016/S0140-6736(12)61228-8 – volume: 29 start-page: 3245 year: 2010 ident: 12796_CR50 publication-title: Stat Med doi: 10.1002/sim.3923 – volume: 62 start-page: 74 year: 2005 ident: 12796_CR34 publication-title: Occup Environ Med doi: 10.1136/oem.2004.013896 – ident: 12796_CR22 – volume: 14 start-page: 2756 year: 1996 ident: 12796_CR37 publication-title: J Clin Oncol doi: 10.1200/JCO.1996.14.10.2756 – volume: 38 start-page: 734 year: 2020 ident: 12796_CR11 publication-title: J Clin Oncol doi: 10.1200/JCO.19.01726 – volume: 38 start-page: 413 year: 2020 ident: 12796_CR39 publication-title: PharmacoEconomics doi: 10.1007/s40273-019-00876-4 – volume: 27 start-page: 1230 year: 2018 ident: 12796_CR51 publication-title: Stat Methods Med Res doi: 10.1177/0962280216658320 – ident: 12796_CR60 doi: 10.4135/9781071909850 – volume: 98 start-page: 144 year: 2010 ident: 12796_CR15 publication-title: Health Policy doi: 10.1016/j.healthpol.2010.06.013 – volume: 17 start-page: 416 year: 2023 ident: 12796_CR31 publication-title: J Cancer Surviv doi: 10.1007/s11764-022-01211-1 – volume: 61 start-page: 463 year: 2018 ident: 12796_CR10 publication-title: Work doi: 10.3233/WOR-182810 – volume: 25 start-page: 30 year: 2023 ident: 12796_CR7 publication-title: Breast Cancer Res doi: 10.1186/s13058-023-01623-6 – volume: 28 start-page: 3866 year: 2021 ident: 12796_CR13 publication-title: Curr Oncol doi: 10.3390/curroncol28050330 – volume: 29 start-page: 406 year: 2019 ident: 12796_CR56 publication-title: J Occup Rehabil doi: 10.1007/s10926-018-9800-z – volume: 29 start-page: 11 year: 2019 ident: 12796_CR24 publication-title: J Occup Rehabil doi: 10.1007/s10926-018-9776-8 – volume: 8 start-page: 115 year: 2011 ident: 12796_CR46 publication-title: Int J Behav Nutr Phys Activity doi: 10.1186/1479-5868-8-115 – start-page: 793 volume-title: Handbook of child psychology: theoretical models of human development year: 2006 ident: 12796_CR58 – ident: 12796_CR18 doi: 10.1002/14651858.CD007569.pub3 – volume: 109 start-page: 465 year: 2022 ident: 12796_CR41 publication-title: Bull Cancer doi: 10.1016/j.bulcan.2021.06.016 – volume: 15 start-page: 507 year: 2005 ident: 12796_CR20 publication-title: J Occup Rehabil doi: 10.1007/s10926-005-8031-2 – volume: 36 start-page: 1868 year: 2018 ident: 12796_CR8 publication-title: J Clin Oncol doi: 10.1200/JCO.2017.77.3663 – volume: 14 start-page: S8 issue: Suppl 3 year: 2014 ident: 12796_CR9 publication-title: BMC Public Health doi: 10.1186/1471-2458-14-S3-S8 – volume: 85 start-page: 365 year: 1993 ident: 12796_CR38 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/85.5.365 – volume: 38 start-page: 302 year: 2020 ident: 12796_CR5 publication-title: J Clin Oncol doi: 10.1200/JCO.19.01856 – volume: 67 start-page: 361 year: 1983 ident: 12796_CR40 publication-title: Acta Psychiatr Scand doi: 10.1111/j.1600-0447.1983.tb09716.x – ident: 12796_CR52 doi: 10.1007/BF03405503 – volume: 21 start-page: 895 year: 2021 ident: 12796_CR19 publication-title: BMC Cancer doi: 10.1186/s12885-021-08613-x – volume: 6 start-page: 35 year: 2018 ident: 12796_CR27 publication-title: Front Public Health doi: 10.3389/fpubh.2018.00035 – volume: 46 start-page: 177 year: 2020 ident: 12796_CR16 publication-title: Scand J Work Environ Health doi: 10.5271/sjweh.3847 – volume: 12 start-page: 140 year: 2019 ident: 12796_CR1 publication-title: J Hematol Oncol doi: 10.1186/s13045-019-0828-0 – volume: 28 start-page: 16 year: 2018 ident: 12796_CR44 publication-title: J Occup Rehabil doi: 10.1007/s10926-017-9697-y – year: 2022 ident: 12796_CR12 publication-title: J Cancer Surviv doi: 10.1007/s11764-022-01197-w – volume: 28 start-page: 4435 year: 2020 ident: 12796_CR14 publication-title: Support Care Cancer doi: 10.1007/s00520-019-05189-y – volume: 24 start-page: 359 year: 2010 ident: 12796_CR42 publication-title: Work Stress doi: 10.1080/02678373.2010.532644 – volume: 21 start-page: 327 year: 2003 ident: 12796_CR48 publication-title: PharmacoEconomics doi: 10.2165/00019053-200321050-00004 – volume: 14 start-page: 87 year: 2016 ident: 12796_CR36 publication-title: Health Qual Life Outcomes doi: 10.1186/s12955-016-0489-4 – volume: 9 start-page: 429 year: 2013 ident: 12796_CR47 publication-title: Alzheimers Dement doi: 10.1016/j.jalz.2012.06.008 – volume: 27 start-page: 261 year: 2004 ident: 12796_CR49 publication-title: Int J Rehabil Res doi: 10.1097/00004356-200412000-00002 – volume: 19 start-page: 166 year: 2009 ident: 12796_CR59 publication-title: J Occup Rehabil doi: 10.1007/s10926-009-9172-5 – volume: 22 start-page: 286 year: 2016 ident: 12796_CR30 publication-title: Evaluation (Lond) doi: 10.1177/1356389016652743 – volume: 301 start-page: 753 year: 2009 ident: 12796_CR6 publication-title: JAMA doi: 10.1001/jama.2009.187 – volume: 27 start-page: 1138 year: 2018 ident: 12796_CR23 publication-title: Psychooncology doi: 10.1002/pon.4611 – ident: 12796_CR25 doi: 10.1177/1757975921993358 – ident: 12796_CR33 doi: 10.4135/9781071909850 – volume: 374 start-page: n2061 year: 2021 ident: 12796_CR21 publication-title: BMJ doi: 10.1136/bmj.n2061 – volume: 75 start-page: 2299 year: 2012 ident: 12796_CR29 publication-title: Soc Sci Med doi: 10.1016/j.socscimed.2012.08.032 – volume: 25 start-page: 1993 year: 2017 ident: 12796_CR17 publication-title: Support Care Cancer doi: 10.1007/s00520-016-3526-2 – volume: 13 start-page: 910779 year: 2022 ident: 12796_CR54 publication-title: Front Psychol doi: 10.3389/fpsyg.2022.910779 – volume: 22 start-page: 1905 year: 2022 ident: 12796_CR55 publication-title: BMC Public Health doi: 10.1186/s12889-022-14271-w – volume: 51 start-page: 243 year: 2000 ident: 12796_CR35 publication-title: Soc Sci Med doi: 10.1016/S0277-9536(99)00452-9 |
| SSID | ssj0017808 |
| Score | 2.4406557 |
| Snippet | Background
Women with breast cancer face many barriers to return to work (RTW) after their cancer. The main objective of the FASTRACS-RCT is to evaluate the... Women with breast cancer face many barriers to return to work (RTW) after their cancer. The main objective of the FASTRACS-RCT is to evaluate the impact of the... Background Women with breast cancer face many barriers to return to work (RTW) after their cancer. The main objective of the FASTRACS-RCT is to evaluate the... BackgroundWomen with breast cancer face many barriers to return to work (RTW) after their cancer. The main objective of the FASTRACS-RCT is to evaluate the... Background: Women with breast cancer face many barriers to return to work (RTW) after their cancer. The main objective of the FASTRACS-RCT is to evaluate the... Abstract Background Women with breast cancer face many barriers to return to work (RTW) after their cancer. The main objective of the FASTRACS-RCT is to... |
| SourceID | doaj hal proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1107 |
| SubjectTerms | Adult Biomedical and Life Sciences Biomedicine Breast cancer Breast neoplasms Breast Neoplasms - psychology Breast Neoplasms - therapy Cancer Cancer Research Cancer survivors Care and treatment Check lists Chemotherapy Chronic diseases Demographic aspects Depression, Mental Diagnosis Employers Employment Exercise Female Health aspects Health promotion Health Promotion and Disease Prevention Humans Intervention Intervention studies Life Sciences Mapping Medical personnel Medical prognosis Medicine/Public Health Middle Aged Multicenter Studies as Topic Oncology Oncology, Experimental Patients Physical activity Prospective Studies Psychological aspects Quality of Life Randomized Controlled Trials as Topic Return to Work Santé publique et épidémiologie Sick Leave Social aspects Social interactions Social support Stress (Psychology) Study Protocol Surgical Oncology Theory-driven evaluation Womens health Work disability prevention Workplace accommodation |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagQogL4t1AAYOQOEDUJE784LZUrIpUKkQB9WY5tlNWahO0yfbAT-HXMuM8aFQBF067ys46iWc8_kae-YaQF74wNrPKx6KsZJznCYtLU5rYMWEzLgD1BzqGrwfi8FAeH6uPF1p9YU5YTw_cT9yu8AYgPUvBbzIAF05xXxnmlRLeVmUeeD4B9YzB1HB-IGQixxIZyXdb8MISK5GRo08oHuezbSiw9U8--eo3TIm8jDcvnZWGLWh5i9wcsCNd9M98m1zx9R1y_cNwOn6X_Azn_3R1IY2RnhkkYDihXUMrY3tKbk9N7Wjbl07RtYddp45BAHO0aGgaTkvMVe-oRZtYv6HI5tCAyVCAuBQgI10usNny3hENCYkhw9NT2PZcc7b64R0dMuBP4WvoC3KPfFm--7y3Hw-9F2LLi7SLLYMZy2QFs57hNlc4A6GbsyWrTJq7xFVcSuMT5lkCn8pCqJuY1GZFVRZSOnafbNVN7bcJlUY4wbmsUgPw0OSlY9KYXHGrSgVDRyQdVaHtQEyO_TFOdQhQJNe9-jSoTwf16Twir6b_fO9pOf4q_RY1PEkipXa4AIamB0PT_zK0iDxF-9B9ferkGPQCTI0xjGMj8jxIIK1GjXk7J2bTtvr90aeZ0MtBqGrgLa0ZyiBgrpCJaya5M5OEdW_ndwNDnb3T_uJA47UkF4kQKj1PYYzRjvXgnFoNiD5D9leWROTZ9DMOjwl3tW82QSbFVgBSReRBb__TrQBSMyG5iMjrcUH8HvzPWnj4P7TwiNzIcBnjkV6xQ7a69cY_Jtfsebdq10-CE_gFbYpbsw priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELboFiEuvB-BAgYhcYCoSZzEDhe0rboqUllVLaDeLMd2lpXapGx2e-Cn8GuZcbwpUUUvnLLKTpw4Hs8j_vwNIW9tpnSiCxvyshJhmkYsLFWpQsO4TnIOUb-jY_h-wKdTcXJSHPoPbq2HVa5tojPUptH4jXwbwpAEKStZ9On8Z4hVo3B11ZfQ2CCbyFSWjsjmzt708KhfR-AiEuutMiLfbsEaC9yRjFx9vMjDdOCOHGt_b5s3fiA08mrceWXN1Lmiyd3_7cQ9cscHoXTcac19csPWD8itL36Z_SH57YAEdP4XHpKeKWRymNFlQyulO25vS1VtaNvtwaILC-6rDkEAwV7UVR-nJYLel1Sjci0-UqSFaED3KMTKFGJPOhlj1ebdY-qQjQ4qain4T9OczX9ZQz2U_hR-ugIjj8i3yd7X3f3QF3EIdZ7Fy1AzeOWJqCCsSNBfZkZBDmh0ySoVpyYyVS6EshGzLIJjoSFnjlSsk6wqMyEMe0xGdVPbp4QKxQ3Pc1HFCuJMlZaGCaXSItdFWUDTAYnXYym1ZzjHQhun0mU6Ipfd-EsYBOnGX6YBed9fc97xe1wrvYMq0ksiN7c70Sxm0k91ya2CJJTF4OkZhMOmyG2lmC0KbnVVpvCYr1DBZLfRtbcwcgy6yhgmxAF54ySQn6NGANBMrdpWfj4-Ggi980JVA73Uyu-ngHeFlF4Dya2BJBgQPbwbaPqgT_vjA4nnopRHnBfxRQxtrDVaeivXykt1Dsjr_m9sHpF7tW1WTibGmgKiCMiTbgL1t4LYnHGR84B8WM-oy8b_PQrPrn-W5-R2gjMcV_2yLTJaLlb2BbmpL5bzdvHSW4g_xxVrIQ priority: 102 providerName: ProQuest |
| Title | Using intervention mapping to facilitate and sustain return-to work after breast cancer: protocol for the FASTRACS multicentre randomized controlled trial |
| URI | https://link.springer.com/article/10.1186/s12885-024-12796-4 https://www.ncbi.nlm.nih.gov/pubmed/39237867 https://www.proquest.com/docview/3102482730 https://www.proquest.com/docview/3101229089 https://hal.science/hal-04707791 https://doaj.org/article/7ea716314293405d96efa3e997ecfb43 |
| Volume | 24 |
| WOSCitedRecordID | wos001307893300007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: Open Access: BioMedCentral Open Access Titles customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: RBZ dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: DOA dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: M~E dateStart: 20010101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: Springer Nature Link customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: RSV dateStart: 20011201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbohhAv3C-BUQxC4oFFJHESO7x106pN2qqqhak8WY7jlEpbgpp2D_wUfi3nOBeIBkjw0kt64sTOudbnfIeQNyZSOtCJcXmaCzcMPeamKlVuxrgOYg5ev4VjOD_lk4lYLJJpUxRWtdnu7Zak1dRWrEX8vgJNKrCaGHH2eBK74YDsgrkTKI6z-Xm3d8CFJ9rymN-e1zNBFqm_08eDL5gOed3XvLZPas3P-O7_3fg9cqdxN-mo5o_75IYpHpBbZ82G-kPy3aYM0NUvmY_0UiFmw5JuSporXaN4G6qKjFZ1tRVdGzBUhQsEmNZFbZ9xmmJ6-4ZqZKP1B4oAECVwGQWvmIKXSccj7M98OKc2h9EmhRoKljIrL1ffTEabpPkL-GhbiTwin8ZHHw-P3aZdg6vjyN-4msE8A5GDAxGgZYwyBdFeplOWKz_MvCyPhVDGY4Z58J5oiI495esgytNIiIw9JjtFWZinhArFMx7HIvcVeJQqTDMmlAqTWCdpAkM7xG-foNQNljm21LiQNqYRsawXXcKiS7voMnTIu-6crzWSx1-pD5AxOkpE4bYHyvVSNkItuVEQbjIfbDoDxzdLYpMrZpKEG52nIdzmS2QrWZe0drpEjoBDGcPQ1yGvLQUicRSY6rNU26qSJ_NZj-htQ5SXMEutmsoJWCsE7-pR7vUoQVXo_tWAv3tzOh6dSjzmhdzjPPGvfBijZX_Z6LNKQhAQIGAs8xzyqvsZh8ccvcKUW0vjY_cAkTjkSS023aXAC2dcxNwh-62M_Bz8z0_h2b-RPye3AxQz3O-L9sjOZr01L8hNfbVZVeshGfAFt69iSHYPjibT2dD-BQPfpidn089Dq0d-AO2lZkY |
| linkProvider | Springer Nature |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3db9MwELe2gYAXvj8KgxkE4gGiJXEaO0gIlcHUal2F2EB9M47tlEpbMpp2CP4U_gj-Ru6cj1FN7G0PPLVKr07i3J3v4t_9jpCntqt0qBPr8TQTXhT5zEtVqjzDuA5jDlG_o2P4POSjkRiPkw8r5HdTC4OwysYnOkdtCo3vyDchDAmRspL5b46-edg1CndXmxYalVrs2B_fIWUrXw_ewfN9Fobb7_e3-l7dVcDTcTeYe5qFEFWKDNa5EB141yhISoxOWaaCyPgmi4VQ1meW-fCZaEjifBXosJulXSEMg3FXyQXw4xwhZHzcJngBF75oCnNEvFmC7xdY_4zMgDyJvWhp8XM9AtqVYPUrAjFPR7mndmjdwrd97X-bsuvkah1i015lEzfIis1vkku7NYjgFvnlYBJ0-hfakx4q5KmY0HlBM6Ur5nJLVW5oWVWY0ZmFxTn3QAChbNT1VqcpQvrnVKPpzF5RJL0owLIoZAIUImu63cOe1Ft71OE2HRDWUogOTHE4_WkNrQsFDuCra59ym3w6l5m5Q9byIrf3CBWKGx7HIgsURNEqSg0TSkVJrJM0gaE7JGh0R-qavx3biBxIl8eJWFb6JuGhS6dvMuqQF-1_jir2kjOl36JKtpLIPO4OFLOJrB2Z5FZBis0C0H8Gwb5JYpspZpOEW52lEVzmBiq0rMp4W_8pe2AbjGG63yFPnASyj-QIb5qoRVnKwd7HJaHntVBWwF1qVVeLwFwhYdmS5PqSJLhHvXw2sKyle-r3hhKP-RH3OU-C4wDGaCxI1j68lCfm0yGP259xeMQl5rZYOJkAOyaIpEPuVgbbngoyD8ZFzDvkZWPBJ4P_-yncP_taNsjl_v7uUA4Ho50H5EqI3gX3N7vrZG0-W9iH5KI-nk_L2SPnmyj5ct6W_Qcez8WY |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELfYQBMvfH8EBjMIiQcWLYmT2OGtDKpNlGqiMO3NcmynVNqSqUn3wJ_CX8udk4ZFAyTEU6v04tTOferufkfIK5soHenM-jwvhB_HAfNzlSvfMK6jlIPX7-AYjid8OhUnJ9nRpS5-V-2-Tkm2PQ2I0lQ2e-emaEVcpHs1aFWBncWIucez1I83yPUYhwZhvD477vMIXARi3Srz2_sG5sih9ve6eeMblkZe9Tuv5EydKRrf_v9N3CG3OjeUjlq-uUuu2fIe2frUJdrvkx-ulIAuLlVE0jOFWA5z2lS0ULpF97ZUlYbWbRcWXVowYKUPBFjuRd38cZpj2XtDNbLX8i1FYIgKuI-Ct0zB-6TjEc5t3p9RV9voikUtBQtqqrPFd2toV0x_Cl_diJEH5Ov4w5f9A78b4-DrNAkbXzPYZyQKcCwitJiJURAFGp2zQoWxCUyRCqFswCwL4DPTEDUHKtRRUuSJEIY9JJtlVdrHhArFDU9TUYQKPE0V54YJpeIs1VmewdIeCddvU-oO4xxHbZxKF-uIVLaHLuHQpTt0GXvkTX_PeYvw8Vfqd8gkPSWic7sL1XIuO2GX3CoIQ1kItp6BQ2yy1BaK2SzjVhd5DH9zB1lMtq2uvY6RI-BWxjAk9shLR4EIHSWWAM3Vqq7l4ezzgOh1R1RUsEutuo4KOCsE9RpQbg8oQYXo4dOA1wd7OhhNJF4LYh5wnoUXIayxFgXZ6blaQnAQIZAsCzzyov8Zl8favdJWK0cT4lQBkXnkUStC_aPAO2dcpNwju2t5-bX4n9_Ck38j3yFbR-_HcnI4_fiU3IxQ4jAlmGyTzWa5ss_IDX3RLOrlc6c8fgJwgWv- |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Using+intervention+mapping+to+facilitate+and+sustain+return-to+work+after+breast+cancer%3A+protocol+for+the+FASTRACS+multicentre+randomized+controlled+trial&rft.jtitle=BMC+cancer&rft.au=Fassier%2C+Jean-Baptiste&rft.au=Guittard%2C+Laure&rft.au=Fervers%2C+B%C3%A9atrice&rft.au=Rouat%2C+Sabrina&rft.date=2024-09-05&rft.issn=1471-2407&rft.eissn=1471-2407&rft.volume=24&rft.issue=1&rft.spage=1107&rft_id=info:doi/10.1186%2Fs12885-024-12796-4&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2407&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2407&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2407&client=summon |